Bristol-myers Squibb Stock News

Related Stocks: LGF.B , NOV , DBI , FTI , PRTY , SSRM , BMY , AR , COTY , GPRE , HP , OLN , CCJ , EAF , TTI , BHF , DIDI , CXM ,

Related Stocks: MDU , LHX , BMY , RDS.A , TFI , SIVR , LLY , SPY , HD , PFE , WMT ,

Related Stocks: BMY , ABC , MCK , THC , NVST , LIVN , CNC , JAZZ , CI , CANO , BDX , FATE , REGN , HUM , DHR , TMO , VEEV , AMGN ,

Mascoma Wealth Management LLC acquired a new stake in Bristol-Myers Squibb (NYSE:BMY) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 1,138 shares of the biopharmaceutical companys stock, valued at approximately $67,000. Other hedge funds have also added to or reduced their stakes in the []

Related Stocks: BMY , ALL , ACGL , BAC , ALXN , AMGN ,

Graphs, TOC, and tables included in the Mental Illnesses Market analysis report help understand the market size, share, trends, growth drivers and market opportunities and challenges. Analysis and discussion of important industry trends, market size, and market share estimates are

Currently, there are many indicators showing that the U.S. stock market is overvalued.

Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway ( BRK.A , Financial) ( BRK.B , Financial) published its third-quarter 13F filing earlier this week, reporting U.S. equity position changes durin

CAMBRIDGE, Mass. and SUZHOU, Jiangsu, China , Nov. 16, 2021 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement-targeted therapies to treat immune-mediated diseases, today announced the appointment of Teri Loxam as Chief Operating Officer (COO) and Chief Financial Officer (CFO). Ms. Loxam will replace interim CFO Matt Gorman and will oversee finance along with several strategic and operational functions of the company. "We are delighted to welcome Teri to the Kira executive team. As Kira continues to build momentum and advance through the clinic, Teri''s wealth of experience across finance, strategy, investor relations and communications will be invaluable" said Frederick Beddingfield , MD, PhD, CEO of Kira Pharmaceuticals. "We will benefit from her strong relationships across the life sciences and investment communities and her strength in operational execution and building teams as we continue to grow and bring much needed therapies to patients." Ms.

Berkshire leader also trimmed AbbVie and Bristol-Myers Squibb holdings Check out Warren Buffett Stock Picks » Download GuruFolio Report of Warren Buffett (Updated on 11/14/2021) Related Stocks: BRK.A , BRK.B , RPRX , FND , CVX , MRK , LBTYK , OGN , CHTR , ABBV , AAPL , BAC , AXP , KO , KHC ,

Related Stocks: BMY , NVDA , FB , WMT , DIS , PFE , ASML , MU , C , REGN ,

Bristol-Myers Squibb Company (NYSE:BMY) price is hovering higher on Monday, November 15, jumping 0.66% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

Canandaigua National Corp increased its position in Bristol-Myers Squibb (NYSE:BMY) by 5.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 87,400 shares of the biopharmaceutical companys stock after acquiring an additional 4,672 shares during the period. Canandaigua National Corps []

Coave Therapeutics appoints Chief Medical Officer and Chief Operating Officer Submitted 15/11/2021 - 9:15am Coave Therapeutics (Coave), a clinical-stage biotechnology company backed by international life science and strategic investors Seroba Life Sciences, Théa Open Innovation, eureKARE, Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital, Sham Innovation Santé/Turenne, has strengthened its leadership team with the appointments of Thomas Blaettler MD, as Chief Medical Officer, and Patricia Françon PhD, to the newly created position of Chief Operating Officer. I am very pleased to welcome Thomas and Patricia to the leadership team at Coave. Their collective accomplishments and deep domain expertise in neuroscience, cell and gene therapy, in addition to their extensive clinical drug development and project management experience will be invaluable as we progress our lead candidate through clinical development and advance our pipeline of novel gene therapies into clinical development targeting rare Ocular and CNS diseases, says Rodolphe Clerval, CEO.